Tumor-infiltrating lymphocytes (TILs) are immune cells that naturally recognize and penetrate tumors to kill cancer cells, making them a promising approach for treating solid tumors. This potential ...

Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study The following represents disclosure ...

The promise of tumor-infiltrating lymphocytes (TIL) therapy is expanding beyond melanoma to a wide range of solid tumors, but the path to clinical success remains complex. Variability in tumor tissue ...

Researchers at Moffitt Cancer Center have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of ...

Cervical cancer remains a global health burden, with over 570,000 new cases and 311,000 deaths annually. Existing treatment options for advanced stages, such as chemotherapy and checkpoint inhibitors, ...

Please provide your email address to receive an email when new articles are posted on . The addition of pembrolizumab to TIL therapy improved response rates among individuals with metastatic ...

A team of researchers from Moffitt Cancer Center has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings, published ...

Exploration of the new classification of hormone receptor-positive breast cancer: Based on the genomic landscape of 2111 early to mid-stage Asian patients. Long-term outcomes in triple-negative breast ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. It’s not common for cancer surgeons to turn their focus ...

Compared to normal tissues, where the expression of ULBP2/5/6 protein is restricted, in non-small-cell lung cancer (NSCLC), head and neck cancer and squamous urothelial carcinoma, the levels of ...